Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma

Autor: Eertink, Jakoba Johanna, Zwezerijnen, Gerben J.C., Wiegers, Sanne E., Pieplenbosch, Simone, Chamuleau, Martine E.D., Lugtenburg, Pieternella J., de Jong, Daphne, Ylstra, Bauke, Mendeville, Matias, Dührsen, Ulrich, Hanoun, Christine, Hüttmann, Andreas, Richter, Julia, Klapper, Wolfram, Jauw, Yvonne W.S., Hoekstra, Otto S., de Vet, Henrica C.W., Boellaard, Ronald, Zijlstra, Josée M.

Publikováno v: Blood, 7(2), 214-223. American Society of Hematology
Blood advances, 7(2), 214-223. American Society of Hematology
On behalf of the PETRA Consortium 2023, ' Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma ', Blood, vol. 7, no. 2, pp. 214-223 . https://doi.org/10.1182/bloodadvances.2022008629, https://doi.org/10.1182/bloodadvances.2022008629

We investigated whether the outcome prediction of patients with aggressive B-cell lymphoma can be improved by combining clinical, molecular genotype, and radiomics features. MYC, BCL2, and BCL6 rearrangements were assessed using fluorescence in situ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10b9411d2c65ff7be0c84b74d1b1b14e
https://doi.org/10.1182/bloodadvances.2022008629

Potential and pitfalls of Zr-89-immuno-PET to assess target status: Zr-89-trastuzumab as an example:89Zr-trastuzumab as an example

Autor: Huisman, Marc C., Menke-van der Houven van Oordt, C. Willemien, Zijlstra, Josée M., Hoekstra, Otto S., Boellaard, Ronald, van Dongen, Guus A.M.S., Shah, Dhaval K., Jauw, Yvonne W.S.

Publikováno v: Huisman, M C, Menke-van der Houven van Oordt, C W, Zijlstra, J M, Hoekstra, O S, Boellaard, R, van Dongen, G A M S, Shah, D K & Jauw, Y W S 2021, ' Potential and pitfalls of Zr-89-immuno-PET to assess target status: Zr-89-trastuzumab as an example : 89 Zr-trastuzumab as an example ', EJNMMI Research, vol. 11, no. 1, 74 . https://doi.org/10.1186/s13550-021-00813-7
EJNMMI Research, 11(1):74. Springer Berlin

Background: 89Zirconium-immuno-positron emission tomography (89Zr-immuno-PET) is used for assessment of target status to guide antibody-based therapy. We aim to determine the relation between antibody tumor uptake and target concentration to improve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::d6c90ae8435ccc53add5e8226673dbb4
https://research.vumc.nl/en/publications/f3ce1d64-5f70-426c-afc8-b3773c9d304c

Baseline radiomics features and MYCrearrangement status predict progression in aggressive B-cell lymphoma

Autor: Eertink, Jakoba J., Zwezerijnen, Gerben J.C., Wiegers, Sanne E., Pieplenbosch, Simone, Chamuleau, Martine E.D., Lugtenburg, Pieternella J., de Jong, Daphne, Ylstra, Bauke, Mendeville, Matias, Dührsen, Ulrich, Hanoun, Christine, Hüttmann, Andreas, Richter, Julia, Klapper, Wolfram, Jauw, Yvonne W.S., Hoekstra, Otto S., de Vet, Henrica C.W., Boellaard, Ronald, Zijlstra, Josée M.

Publikováno v: Blood Advances; 20230101, Issue: Preprints